Charles Sigal

Dr. Charles E.
Sigal is an Independent Director at Alnylam Pharmaceuticals, Inc., an Independent Director at Vir Biotechnology, Inc., an Independent Director at Affinia Therapeutics, Inc., a Manager at Segal Family Investments LLC, a Member-Drug Discovery & Development Forum at National Academy of Medicine (United States) and a Member-President Council at The J.
David Gladstone Institutes.
He is on the Board of Directors at Alnylam Pharmaceuticals, Inc., Tessera Therapeutics, Inc., Vir Biotechnology, Inc., Affinia Therapeutics, Inc., Melanoma Research Alliance, Medarex, Inc. and University Medical Center.
Dr. Sigal was previously employed as an Independent Non-Executive Director by Surface Oncology, Inc., an Independent Non-Executive Director by Adaptimmune Therapeutics Plc, a Non-Executive Director by Adaptimmune Ltd., an Independent Director by Spark Therapeutics, Inc., a Director, Chief Scientific Officer & Executive VP by Bristol Myers Squibb Co., a Chief Executive Officer, Vice President-R&D by Mercator Genetics, Inc., and a Trustee by Penn Medicine Princeton Health.
He also served on the board at Mead Johnson Nutrition Co. He received his undergraduate degree from Purdue University, a graduate degree from Purdue University, a doctorate degree from The University of Chicago and a doctorate degree from Purdue University.